ProCE Banner Activity

My Take on Key Therapy Issues for Patients With CLL During COVID-19

Clinical Thought
Our understanding of how COVID-19 affects our patients with CLL continues to evolve. Here, I share my perspective on treatment modifications during the pandemic, using IVIg as COVID-19 prophylaxis, the role of BTK inhibition, and counseling patients on COVID-19 risk.

Released: September 14, 2020

Expiration: September 13, 2021

No longer available for credit.

Share

Faculty

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Gilead Sciences, Janssen, Juno, and Pharmacyclics and funds for research support from AbbVie, AstraZeneca, BeiGene, Genentech, Juno, MingSight, Oncternal, TG Therapeutics, and Verastem.